I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK and Australia):

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EURETINA 2021

-
10:00 AM
Duration 4mins Virtual
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial
Jordi Monés, Shamika Gune, Mauricio Maia, Han Ting Ding, Merce Morral, Matts Kågedal, and Katie Maass

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Deep Learning Model for Automated Screening of Moderately Severe and Severe Non-proliferative Diabetic Retinopathy From 7-Field Colour Fundus Photographs
Benmansour F, Yang Q, Damopoulos D, Anegond N, Neubert A, Novosel J, Armendariz B, Ferrara D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Machine Learning Model to Predict the Development of Clinically Significant Macular Edema in Patients With Mild Non-proliferative Diabetic Retinopathy
Damopoulous D, Mendes L, Torcato S, Neubert A, Armendariz B, Weikert R, Ferrara D, Cunha-Vaz J, Benmansour F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Prediction of Geographic Atrophy Lesion Area and Growth Rate From Multimodal Imaging Using Deep Learning
Anegondi N, Steffen V, Rabe C, Ferrara D, Gao S, Yang Q

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
The Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for nAMD: Data Update and Key Surgical Pearls
Marcus D, Barteselli G, Kaufman D, Fung A, Gune S, Makadia S, Menezes A, Malhotra V, Willis J, Morral M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Simultaneous Ang-2/VEGF-A inhibition prevents subretinal fibrosis progression in preclinical mouse models of choroidal neovascularization (CNV)
Linder M, Foxton R, Uhles S, Revelant F, Lazendic M, Canonica J, Garcia Garrido M, Westenskow P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Towards Automated Imaging Analysis: Assessing Accuracy and Reliability of Lesion Segmentation by Multimodal Deep Learning Networks in Patients With Geographic Atrophy in the Proxima A and Proxima B Natural History Studies
Spaide T, Patil J, Jiang J, Anegondi N, Kawczynski M, Steffen V, Gao S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:01 PM
Duration 4mins Virtual
Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Khanani A, Blotner S, Gune S, Morral M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:05 PM
Duration 4mins Virtual
Efficacy, Safety and Durability of Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Results From the Phase 3 TENAYA and LUCERNE Trials
Holz F, Heier J, Quezada Ruiz C, Silverman D, Ives J, Basu K, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:01 PM
Duration 4mins Virtual
Design and Rationale of the YOSEMITE and RHINE Trials: Two Phase 3 Studies of Faricimab in Patients With Diabetic Macular Edema
David Silverman, Carlos Quezada Ruiz, Jeffrey R. Willis, Jane Ives, Karen Basu, Balakumar Swaminathan, Aachal Kotecha, Heather Boston, Hugh Lin

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:05 PM
Duration 4mins Virtual
Exploring Ang-2 Signalling in Vascular Stability in Patients With DME Receiving Faricimab in Phase 2 and Phase 3 Trials
Loewenstein A, Sheth V, Csaky K, Edmonds R, Chang M, Willis J, Haskova Z, Westenskow P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:00 PM
Duration 4mins Virtual
Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab
Chakravarthy U, Regillo C, Blotner S, Gune S, Morral M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Barriers to adherence to age-related macular degeneration and diabetic macular edema management plans: A multi-national qualitative study
Peto T, Lanar S, Lambert J, Lewis H, Kosmas C, Mirt Dabic M, Kotecha A, Paris L, Van den Brande I, Gentile B, Chi G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Development of a Short Form of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)
Singerman L, Gugiu C, Tschosik E, Doll H, Drawnel F, Singerman B, Gentile B

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Role of Dual Inhibition of Ang-2 and VEGF-A in Patients with Macular Edema Due to Branch or Central/Hemiretinal Retinal Vein Occlusion: Rationale and Design of the Faricimab Phase 3 BALATON and COMINO Trials
Hattenbach L, Jain N, Khanani A, Löwenstein A, Seres A, Tadayoni P, Abreu F, Haskova Z, Lin H, Silverman D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:45 PM
Duration 49mins Virtual
Watch Dr. Schlottmann, Dr. Monés and Prof Joussen discuss targeting the Ang-Tie pathway for the management of retinal diseases
Schlottmann P, Monés J, Joussen A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:15 AM
Duration 4mins Virtual
Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema: One-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Tadayoni R, Wykoff C, Haskova Z, Silverman D, Ives J, Basu K, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:15 PM
Duration 4mins Virtual
Faricimab Personalised Treatment Interval (PTI) Dosing Dynamics Illustrated With Patient Case Profiles: YOSEMITE and RHINE Phase 3 Diabetic Macular Edema (DME) Trials
Pearce I, Jaffe G, Gerendas B, Asik K, Abreu F, Silverman D, Haskova Z, Scheidl S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:33 PM
Duration 4mins Virtual
Dual Anti-Ang-2/VEGF Neutralisation Prevents Vascular Leakage and Cell Death in a Mouse Retinal Ischaemia/Reperfusion Injury Model and Reduces Subretinal Macrophage Infiltration in a Spontaneous Model of Choroidal Neovascularisation
Canonica J, Shamugam S, Lin C, Antonetti D, Foxton R, Uhles S, Westenkow P, Abcouwer S, Garcia Garrido M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:00 PM
Duration 45mins Virtual
Watch the Roche EURETINA 2021 symposium on 'Optimising nAMD management through longer-acting therapies'
Laidlaw A, Holekamp N

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:01 PM
Duration 4mins Virtual
Design and Rationale of the TENAYA and LUCERNE Trials: Two Phase 3 Studies of Faricimab, a Dual Angiopoietin-2 and VEGF-A Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration
David Silverman, Carlos Quezada Ruiz, Jeffrey R. Willis, Jane Ives, Karen Basu, Balakumar Swaminathan, Aachal Kotecha, Heather Boston, Hugh Lin

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon